Survival
Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review)
International Journal of Oncology 2025 March [Link] Dimitrios Andreikos, Demetrios A Spandidos, Vasiliki Epameinondas Georgakopoulou Abstract Malignant mesothelioma (MM) is a rare but aggressive cancer linked to asbestos exposure and characterized by advanced‑stage disease at presentation. Despite advances in treatment, prognosis remains abysmal, highlighting the imperative for the development of novel biomarkers and treatment approaches.…
Read MoreCD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study
Journal of Thoracic Disease 2025 January 24 [Link] Yuko Aoki, Ken Arimura, Kenzo Hiroshima, Yasuto Sato, Mitsuko Kondo, Etsuko Tagaya Abstract Background: CD276 is an immune checkpoint, and immune checkpoint inhibitors (ICIs) targeting CD276 have been tested against various cancers. However, the precise role of CD276 in mesothelioma subtypes is unknown. This study aimed to…
Read MorePrognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
BMC Cancer 2025 February 14 [Link] Zhang Xinjing, Gong Lei, Li Xinbao, Ji Zhonghe, Yang Zhiran, Gao Chao, Zhang Kai, Yan Lijun, Yan Guojun, Yu Junhui, Zhang Yanbin, An Songlin Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for…
Read MorePrognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network
Cancers 2025 January 30 [Link] Anello Marcello Poma, Rossella Bruno, Iacopo Petrini, Iosè Di Stefano, Alessandra Celi, Andrea Sbrana, Sabrina Cappelli, Antonio Chella, Franca Melfi, Marco Lucchi, Greta Alì Abstract Background. The Hippo pathway is the most frequently altered signaling in pleural mesothelioma (PM). Epithelioid PM (ePM) is associated with better outcome than non-epithelioid subtypes,…
Read MoreA Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials
Cancers 2025 February 3 [Link] Andrea Messori, Sabrina Trippoli, Eugenia Piragine, Sara Veneziano, Vincenzo Calderone Abstract Background: In unresectable pleural mesothelioma, pemetrexed+cisplatin as first line is considered the standard of care, but novel treatments have been recently proposed. Methods: Our objective was to compare, albeit indirectly, the results of randomized controlled trials on overall survival…
Read MoreCurrent Status of Staging and Restaging Malignant Pleural Mesothelioma
Seminars in Nuclear Medicine 2025 March [Link] Egesta Lopci Malignant pleural mesothelioma (MPM) is the most frequent aggressive tumor affecting the pleura, accounting for over 38,000 deaths worldwide. It originates from the mesothelial cells and is mostly associated to asbestos exposure. Depending on the extent of the disease, the management of MPM varies from surgical…
Read MoreRadiotherapy of the pleural cavity in patients with primary and secondary malignancies of the pleura
Reports of Practical Oncology and Radiotherapy 2024 October 3 [Link] Dimcho Georgiev, Marija Jankova, Bozhidar Krastev, Svetlana Bilyukova Abstract Background: Although there have been various attempts to find appropriate treatment from best conservative care to multimodal treatments, curative outcomes remain poor. Materials and methods: 30 patients with primary and secondary malignant tumors of the pleura…
Read MoreThe Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis
Medicina 2025 January 16 [Link] Nadiye Sever, Sedat Yıldırım, Ali Fuat Gurbuz, Delyadil Karakaş Kılıç, Esra Zeynelgil, Yunus Emre Altintaş, Berivan Deniz Çimik, Yeşim Ağyol, Ali Kaan Güren, Pınar Erel, Erkam Kocaaslan, Burak Paçacı, Mustafa Alperen Tunç, Abdussamet Çelebi, Nazım Can Demircan, Selver Işık, Rukiye Arıkan, Murat Araz, Serdar Karakaya, Murat Sarı, Osman Köstek, İbrahim…
Read MorePreclinical Efficacy and Proteomic Prediction of Molecular Targets for s-cal14.1b and s-cal14.2b Conotoxins with Antitumor Capacity in Xenografts of Malignant Pleural Mesothelioma
Marine Drugs 2025 January 10 [Link] Angélica Luna-Nophal, Fernando Díaz-Castillo, Vanessa Izquierdo-Sánchez, Jesús B Velázquez-Fernández, Mario Orozco-Morales, Luis Lara-Mejía, Johana Bernáldez-Sarabia, Noemí Sánchez-Campos, Oscar Arrieta, José Díaz-Chávez, Jorge-Ismael Castañeda-Sánchez, Alexei-Fedorovish Licea-Navarro, Saé Muñiz-Hernández Abstract Malignant pleural mesothelioma (MPM) is a rare neoplasm with increasing incidence and mortality rates. Although recent advances have improved the overall…
Read MoreFollow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA
ESMO Open 2025 February [Link] L H Douma, M M Hofman, F Zwierenga, T M T Zondervan, A I G Buma, H Schouwink, D W Dumoulin, J A Burgers, I Smesseim, J G J V Aerts, C J de Gooijer Abstract Background: Diffuse pleural mesothelioma (dPM) is an aggressive malignancy, primarily treated with palliative systemic…
Read More